MARKET

SLDB

SLDB

Solid Bioscience
NASDAQ
13.32
-0.93
-6.53%
After Hours: 13.07 -0.25 -1.88% 17:50 03/28 EDT
OPEN
14.82
PREV CLOSE
14.25
HIGH
15.05
LOW
12.89
VOLUME
871.56K
TURNOVER
0
52 WEEK HIGH
15.05
52 WEEK LOW
1.810
MARKET CAP
502.92M
P/E (TTM)
-2.7584
1D
5D
1M
3M
1Y
5Y
William Blair starts Solid Biosciences at outperform
Healthcare William Blair starts Solid Biosciences at outperform rating. Firm cites its market opportunities in Duchenne muscular dystrophy, and rare cardiac diseases. William Blair set a fair value of $40 for the stock. The investment firm sees Solid as a ‘fast follower’ in DMD.
Seeking Alpha · 23h ago
Solid Biosciences Price Target Announced at $40.00/Share by William Blair
Dow Jones · 1d ago
Solid Biosciences Initiated at Outperform by William Blair
Dow Jones · 1d ago
William Blair Initiates Coverage On Solid Biosciences with Outperform Rating, Announces Price Target of $40
Benzinga · 1d ago
Weekly Report: what happened at SLDB last week (0318-0322)?
Weekly Report · 4d ago
Cautious Optimism Amidst Clinical Progress and Regulatory Hurdles for Solid Biosciences
TipRanks · 03/19 05:38
Solid Biosciences Price Target Raised to $21.00/Share From $8.00 by Barclays
Dow Jones · 03/18 10:35
Solid Biosciences Is Maintained at Overweight by Barclays
Dow Jones · 03/18 10:35
More
About SLDB
Solid Biosciences Inc. is a life sciences company that is focused on developing transformative treatments to improve the lives of patients with neuromuscular and cardiac diseases. SGT-001 and SGT-003 are its gene transfer candidates. Its neuromuscular and cardiac programs, including SGT-003, a differentiated gene transfer candidate, for the treatment of Duchenne, AVB-202, a gene transfer candidate for the treatment of Friedreichs ataxia, and AVB-401 for BAG3 mediated dilated cardiomyopathy. Its SGT-003 are designed to address the underlying genetic cause of Duchenne by delivering a synthetic transgene that produces dystrophin-like protein that is only expressed in muscles of the body, including cardiac and respiratory muscles. In addition to gene transfer candidates, the Company has development programs focusing on platform technologies, including novel capsid libraries and dual gene expression, a technology that allows to package multiple transgenes into one vector.

Webull offers Solid Biosciences Inc stock information, including NASDAQ: SLDB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLDB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLDB stock methods without spending real money on the virtual paper trading platform.